The Tissue Culture Core will serve all five projects in this program project. Many studies proposed in these projects will require cultured neuronal cell lines or primary neurons or glia. The Core has considerable experience in growing and maintaining different types of cells. Our cell culture inventory consists of over 1,700 cell lines, over 130 hybridoma cell lines that produce monoclonal antibodies to apolipoproteins, lipoprotein receptors, and other proteins, and over 90 cell lines transfected with constructs that express different isoforms of apolipoprotein E, amyloid precursor protein, tau, or huntingtin or variants of those proteins. An online version of the inventory is available to all projects for searching and requesting cell lines. The Core will prepare the media and reagents used in culture studies (Aim 1), provide and maintain the equipment required to prepare and grow neuronal cultures (Aim 2), assist in transfection of different cell lines (e.g., Neuro-2a, B103, C6, U87, HEK293T, and COS) with DMA constructs provided by investigators (Aim 3), assist in culturing primary neurons and glia (Aim 4), and help grow hybridoma cell lines for monoclonal antibody production and HEK293 cells for lentivirus production (Aim 5). The smooth operation of the Core and its assistance with many aspects of tissue culture studies are of fundamental importance to the successful outcome of the program project.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG022074-10
Application #
8377826
Study Section
Special Emphasis Panel (ZAG1-ZIJ-3)
Project Start
Project End
2013-11-30
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
10
Fiscal Year
2012
Total Cost
$140,728
Indirect Cost
$67,048
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Valera, Elvira; Spencer, Brian; Masliah, Eliezer (2016) Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 13:179-89
Spencer, Brian; Kim, Changyoun; Gonzalez, Tania et al. (2016) α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet 25:1100-15
Spencer, Brian; Desplats, Paula A; Overk, Cassia R et al. (2016) Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 36:7971-84
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Spencer, Brian; Potkar, Rewati; Metcalf, Jeff et al. (2016) Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem 291:1905-20
Valera, Elvira; Masliah, Eliezer (2016) Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 139 Suppl 1:346-352
Valera, E; Monzio Compagnoni, G; Masliah, E (2016) Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol 42:95-106
Valera, Elvira; Mante, Michael; Anderson, Scott et al. (2015) Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation 12:93
Eleuteri, Simona; Di Giovanni, Saviana; Rockenstein, Edward et al. (2015) Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease. Neurobiol Dis 74:144-57
Dhungel, Nripesh; Eleuteri, Simona; Li, Ling-Bo et al. (2015) Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein. Neuron 85:76-87

Showing the most recent 10 out of 252 publications